Literature DB >> 6142305

Steroid-hormone receptors and survival after first relapse in breast cancer.

A Howell, D M Barnes, R N Harland, J Redford, V H Bramwell, M J Wilkinson, R Swindell, D Crowther, R A Sellwood.   

Abstract

Oestrogen receptors were measured in the primary breast tumours of 508 patients and progesterone receptors in those of 486 patients. Survival from mastectomy was significantly longer in patients with receptor-positive tumours. There was no significant difference between patients with receptor-positive and receptor-negative tumours in the relapse-free interval, but survival from first relapse was longer in patients with receptor-positive tumours. Axillary node status and tumour size indicated the probability of relapse but did not influence the length of survival after relapse. Response to tamoxifen or ovarian ablation was known in 65 of the 137 patients who relapsed. Survival from first relapse was significantly longer in patients who both responded to hormone therapy and had receptor-positive tumours. Patients who did not respond to hormone therapy and had receptor-positive tumours had the same survival characteristics as those with receptor-negative tumours who did not respond.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6142305     DOI: 10.1016/s0140-6736(84)90995-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  42 in total

1.  Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer.

Authors:  Walter Schippinger; Peter Regitnig; Nadia Dandachi; Klaus-Dieter Wernecke; Thomas Bauernhofer; Hellmut Samonigg; Farid Moinfar
Journal:  Virchows Arch       Date:  2006-04-21       Impact factor: 4.064

2.  Breast cancer incidence in young women by estrogen receptor status and race.

Authors:  J L Stanford; R S Greenberg
Journal:  Am J Public Health       Date:  1989-01       Impact factor: 9.308

3.  Compliance of physicians and patients with a consensus protocol for treatment of advanced breast cancer.

Authors:  F Porzsolt; G Meuret; E D Kreuser; S Mende; L Buchelt; P Strigl; M Redenbacher; F Klumpp; M Schmelz; R Knöchelmann
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Local recurrence of breast cancer: treatment of nine patients with a recurrence in the skin flap of the chest wall.

Authors:  T Naruse; A Koike; A Miyashita; K Matsumoto; K Suzumura; T Kanemitsu; K Kato; S Yamamoto
Journal:  Jpn J Surg       Date:  1987-03

5.  Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up.

Authors:  J M Raemaekers; L V Beex; A J Koenders; G F Pieters; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

6.  Estradiol and progesterone receptors in breast cancer: prognostic value after relapse.

Authors:  J Bonneterre; D Horner; J P Peyrat; B Vandewalle; L Cambier; A Demaille
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  The clinical course of lung metastases from breast cancer.

Authors:  O K Schlappack; M Baur; G Steger; C Dittrich; K Moser
Journal:  Klin Wochenschr       Date:  1988-09-01

Review 8.  The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer.

Authors:  R Vihko; A Alanko; V Isomaa; A Kauppila
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

9.  Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy.

Authors:  J F Robertson; A R Dixon; R I Nicholson; I O Ellis; C W Elston; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: the role of adjuvant chemotherapy.

Authors:  J M Raemaekers; L V Beex; G F Pieters; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.